Ozempic shown to reduce drinking in first trial in alcohol-use disorder
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...
Health Rounds: Hormone delivery via skin patch may ease prostate cancer treatment side effects
When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...
Diet drug boom weighs heavily on state budgets
The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive ...
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...
Why Eli Lilly and Company (LLY) is the Best Long-Term Growth Stock to Buy Now
We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...
Stopping Alzheimer’s Before It Starts: Landmark Trial Enrolls First Participants
WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms arise Researchers at Washington University School of Medicine in St. Louis have ...
MM&M20h
How new direct-to-consumer platforms are changing pharma’s relationships with patients
New DTC platforms like LillyDirect and PfizerForAll are triggering a paradigm shift in how pharma companies connect with patients.
MarketBeat on MSN23h
GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends
The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...
Could obesity drugs help with alcohol cravings? New study suggests potential.
The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not ...
labiotech12h
From AI protein prediction to de novo creation: Latent Labs emerges from stealth
Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...
Three reasons Nvidia's stock is still compelling, and why it could rise 30% in the next year
We ran that screen on Feb. 15 last year, using data as of the market close the previous day. Nvidia's (NVDA) stock has returned 80% from Feb. 14, 2024, through Tuesday, while the S&P 500 SPX has ...